Andere talen SCD Co., Ltd.

Aandelen

A042110

KR7042110007

slotkoers Korea S.E. Andere beurzen 00:00:00 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.488 ^KRW	-0,60%		+0,47%	-15,12%

03/04	Schroder European Real Estate Investment Trust herfinanciert lening ter waarde van 9 miljoen euro	MT
01/02	SeaStar Medical krijgt Canadees octrooi voor technologie voor celgestuurde therapie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Schroder European Real Estate Investment Trust Refinances EUR9 Million Loan	03/04
SeaStar Medical Gets Canadian Patent Covering Technology for Cell-Directed Therapy	01/02
Pfizer : va présenter de nouvelles données en hématologie	03/11
SeaStar Medical's Selective Cytopheretic Device Considered Approvable by the US FDA for Pediatric AKI and Sepsis Treatment	03-10-23
Schroder European Real Estate Investment Trust Posts Lower Property Portfolio Valuation as of June 30	17-07-23
Schroder European Real Estate Investment Trust Swings to Fiscal H1 Loss	28-06-23
SCD Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	10-05-23
SeaStar Medical Holding Shares Drop After US FDA Rejects Application for Pediatric Selective Cytopheretic Device	10-05-23
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group	13-04-23
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group	12-04-23
Schroder European Real Estate Investment Trust Posts Lower FY22 NAV	23-03-23
Schroder European Real Estate Investment Trust Buys EUR11 Million Warehouse in Netherlands	20-03-23
China Fines Five Banks 388 Million Yuan Over Irregularities	20-02-23
SeaStar Medical Shares Rise 20% After FDA Grants IDE Application	09-02-23
National Bank Begins Coverage on Lycos Energy	19-12-22
Pfizer : finalise l'acquisition de Global Blood Therapeutics	05-10-22
Graphite Bio Gets Fast Track Designation for GPH101 Sickle Cell Treatment	03-05-22
Editas Medicine Secures FDA Rare Pediatric Disease Designation for EDIT-301 for Beta Thalassemia	26-04-22
Global Blood Therapeutics's Oxbryta Gets European Approval for Treatment of Hemolytic Anemia in Patients With SCD	16-02-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SCD Co., Ltd.

Aandelen

A042110

KR7042110007

Andere talen

Filters